Innovative Blood Purification Method Targets Antibiotic-Resistant Bacteria Using Artificial Clots
Researchers have developed a novel blood purification device that effectively removes antibiotic-resistant bacteria using artificial clots, offering a promising new treatment for bloodstream infections and sepsis.
A groundbreaking extracorporeal blood purification technology has been developed by researchers at UNIST, aiming to combat bloodstream infections and sepsis caused by antibiotic-resistant bacteria. This novel approach uses a specialized device that captures bacteria directly from the bloodstream by utilizing artificial, clot-like surfaces designed to attract and trap bacteria as blood circulates outside the body. Published in Advanced Science, the study demonstrates that the device—called the eCDTF—effectively removes over 90% of major pathogenic bacteria, including drug-resistant strains like MRSA and bacteria originating from fecal matter.
Led by Professor Joo H. Kang from the Department of Biomedical Engineering, the research involves extracting infected blood through an extracorporeal circuit similar to dialysis. The device incorporates a spiral structure filled with artificial blood clots composed solely of plasma proteins—without cellular components like white blood cells—that attract bacteria via a mechanism known as margination. This process causes small, rigid bacteria to migrate towards the device's surface, enabling efficient bacterial removal.
Preclinical tests on rats infected with methicillin-resistant Staphylococcus aureus (MRSA) showcased remarkable results. When treated with the device for just three hours, the rats exhibited significant reductions in bacterial counts and inflammatory markers. While untreated rats succumbed within a week, those treated twice with the device achieved a 100% survival rate.
The team’s insights into blood flow dynamics inspired this design, with the researchers hypothesizing that bacteria could be directed and removed similarly to platelets. Professor Kang highlighted the potential of this technology to eliminate pathogenic bacteria without relying on antibiotics, which is especially crucial given the rise of antibiotic resistance. This innovative method could revolutionize early intervention for bloodstream infections, reducing the risk of progression to sepsis and organ failure.
More details on the research can be found in the publication: Bong Hwan Jang et al., "Red Blood Cell-Induced Bacterial Margination Improves Microbial Hemoadsorption on Engineered Cell-Depleted Thrombi," Advanced Science (2025). Source: https://medicalxpress.com/news/2025-05-blood-purification-technique-antibiotic-resistant.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Red Blood Cells Play Active Role in Blood Clot Contraction, Challenging Old Beliefs
New study uncovers the active role of red blood cells in blood clot contraction, challenging longstanding beliefs and opening new avenues for treating clotting disorders.
Specialized Nervous System Macrophages Help Maintain Fat Health and Reduce Inflammation with Age
New research reveals how nerve-associated macrophages in fat tissues help maintain metabolic health and reduce inflammation as mice age, offering promising insights into combating age-related metabolic diseases.
Major Update Incorporates Optic Nerve in Multiple Sclerosis Diagnostic Criteria
A major revision to multiple sclerosis diagnostic criteria now includes the optic nerve as a key site for lesion dissemination, enhancing early and accurate diagnosis using advanced imaging and biomarkers.
Evolocumab Shows No Benefit in Preventing Vein Graft Disease After Coronary Bypass Surgery, Major Trial Finds
A recent trial reveals that evolocumab, despite significantly lowering LDL cholesterol, does not reduce vein graft disease rates after coronary artery bypass surgery, pointing to the need for novel treatment strategies.